Key result
Pentoxifylline use in acute MI is not associated with reduced in-hospital mortality.
Why the study?
Pentoxifylline has been proposed as adjunctive therapy in acute myocardial infarction, but its effect on mortality and potential differences across patient phenotypes remained unclear.
Does adjunctive pentoxifylline use reduce in-hospital mortality in patients with acute myocardial infarction in the intensive care unit?
Observational (n=1,684)
Does adjunctive pentoxifylline use reduce in-hospital mortality in patients with acute myocardial infarction in the intensive care unit?
Adjunctive pentoxifylline use in the intensive care unit was not associated with reduced in-hospital mortality in patients with acute myocardial infarction, either overall or across inflammatory, metabolic, or infarct-defined subgroups.
Answers are grounded in this paper and cite their sources.
Should not yet change acute myocardial infarction management; leaves open any adjunctive role for pentoxifylline pending randomized trials.
Background: Pentoxifylline, a hemorheological drug with anti-inflammatory properties, has been proposed as adjunctive therapy in acute myocardial infarction, yet its effect on mortality along with any differences in patient phenotypes remain unclear. Methods: We carried out a registry-based study on 1700 patients with acute myocardial infarction, of which 1684 had a known exposure status to pentoxifylline. The admission-time confounders were analyzed using 1:1 propensity-score matching (PSM) to balance baseline characteristics between pentoxifylline users and non-users. We employed an extreme gradient boosting (XGBoost) model on a hold-out set along with explanations from SHapley Additive exPlanations and Accumulated Local Effects analyses. Results: In the PSM-matched pair analysis, mortality was observed to be 16.4% with and 15.4% without pentoxifylline (risk difference: 1.1% [95% CI: −5.2, 7.4]; odds ratio: 1.09% [95% CI: 0.68, 1.75]. Sensitivity analyses were concordant with the overall findings. Neither any subgroup interaction nor heterogeneity was observed with causal forest. The XGBoost model demonstrated good discriminatory performance (test-set AUC: 0.834, 95% CI: 0.785–0.884). Conclusions: In the present analysis, pentoxifylline use in the intensive care unit was not associated with a reduction in the in-hospital mortality both in overall or in any of the inflammatory, metabolic or infarct-defined subgroup.
No takes yet. Share an insight, caveat, or question.
Sridharan et al. (2026) conducted an observational in Acute myocardial infarction (n=1,684). Pentoxifylline vs. Pentoxifylline non-users was evaluated on In-hospital mortality (OR 1.09, 95% CI 0.68-1.75). Pentoxifylline use in acute MI was not associated with reduced in-hospital mortality compared with non-use (16.4% vs 15.4%; OR 1.09, 95% CI 0.68-1.75).
Synapse has enriched 10 related papers. Consider them for comparative context: